The federal government is moving to reschedule cannabis from Schedule I to Schedule III, a shift with profound implications for the scientific community. This change streamlines DEA registration and acquisition processes, significantly reducing barriers that have historically impeded clinical research. Explore the regulatory evolution and logistical impacts for licensed researchers.